Daewoong Pharmaceutical Unveils Phase 2 Trial Progress on Bersiporocin
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and other regions, with over 50% of participants identified as Asian.
- Selectively inhibits collagen synthesis via PRS targeting, aiming to suppress fibrosis progression.
Daewoong Pharmaceutical, led by Co-CEOs Seongsoo Park and Chang-Jae Lee, has recently shared interim findings from a critical Phase 2 clinical trial of its investigational candidate, Bersiporocin (DWN12088), targeting idiopathic pulmonary fibrosis (IPF). These results were presented at the American Thoracic Society (ATS) International Conference, offering insights into patient demographics that reflect a more global perspective.
During the ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT," Dr. Jinwoo Song, a distinguished Professor of Pulmonology and global Coordinating Investigator for this study, highlighted the trial's focus on diverse participant characteristics. The study features approximately 70% of trial participants receiving Bersiporocin alongside established antifibrotic therapies such as nintedanib or pirfenidone, while the remaining 30% are without concurrent medication. This distinct grouping allows for a more comprehensive evaluation of treatment response across different ethnicities, notably including over half of the 102 participants being Asian.
Conducted across 30 sites in the U.S. and additional regions, the ongoing, randomized, double-blind, placebo-controlled Phase 2 study aims to explore the efficacy and safety of Bersiporocin by administering 150 mg of the drug or a placebo twice daily for 24 weeks. Evaluations will center on vital capacity changes and various clinical endpoints. As recent as April 2025, 80 patients, representing around 80% of the target size, had successfully registered for the trial.
Bersiporocin stands out as a first-in-class oral antifibrotic agent developed by Daewoong Pharmaceutical. It operates by specifically inhibiting Prolyl-tRNA Synthetase (PRS), a crucial enzyme responsible for collagen production. This precise targeting is thought to disrupt the fibrotic process more efficiently, offering promising disease management with reduced unintended effects. This positions Bersiporocin as a pioneering option in the antifibrotic therapy landscape.
This innovative drug's promise has garnered Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA), alongside Fast Track designation from the FDA, mandating its potential impact as a globally relevant IPF treatment solution.
Professor Jinwoo Song emphasized the broader implications of this investigation, noting, "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients. We eagerly anticipate developing safer and more effective solutions for individuals with IPF."
Adding to this sentiment, CEO Seongsoo Park mentioned, "Bersiporocin signifies a significant advancement in antifibrotic therapies by directly addressing the fibrosis root causes through PRS inhibition. We pledge our commitment to furthering this initiative to reshape the global treatment framework for IPF."
Frequently Asked Questions
What is Bersiporocin?
Bersiporocin is an investigational oral antifibrotic drug developed by Daewoong Pharmaceutical, targeting idiopathic pulmonary fibrosis.
What stage is the clinical trial for Bersiporocin in?
The Phase 2 clinical trial is currently ongoing, enrolling diverse participants for comprehensive data collection.
How many participants are currently enrolled in the trial?
The study aims to enroll 102 patients, with 80 already registered as of April 2025.
Why is racial diversity important in this clinical trial?
Diverse racial representation allows for a nuanced understanding of how different ethnic groups respond to the treatment, enhancing benefits across populations.
What are the potential benefits of Bersiporocin?
Bersiporocin aims to provide effective treatment for IPF by selectively inhibiting the collagen synthesis process, potentially with fewer side effects.
